Survey for Government Policies Regarding Strategies for the Commercialization and Globalization of Digital Therapeutics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수영 | - |
dc.contributor.author | 문종윤 | - |
dc.contributor.author | 신재용 | - |
dc.contributor.author | 심정연 | - |
dc.contributor.author | 김미림 | - |
dc.contributor.author | 장지은 | - |
dc.date.accessioned | 2022-01-31T02:40:47Z | - |
dc.date.available | 2022-01-31T02:40:47Z | - |
dc.date.created | 2022-01-18 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83391 | - |
dc.description.abstract | Purpose: This study was conducted to build a direction for government policies regarding strategies for the commercialization of digital therapeutics in Korea, as well as its globalization. Materials and Methods: The study included 37 participants from the Korea Digital Health Industry Association (KODHIA). The data was based on a survey conducted in 2020 targeting employees of companies engaged in the digital health industry in Korea. Participants were asked about their involvement in product development of digital therapeutics and their opinion about the growing motivator for digital therapeutics in Korea and the global market. Results: According to our data, among subjects not involved in making digital therapeutics products, the main reason for not being involved was the lack of experts (73.9%) and difficulty in licensing (73.9%). Responses concerning the priority area in need of national support were R&D funding (43.2%), and the next was licensing guidance and simplifying regulations (24.3%). Possible difficulties of overseas market expansion were the unfamiliarity in digital therapeutics technology verification and licensing structures of foreign countries (73%), and concerns regarding the level of recognition of clinical trials and technology in Korea from overseas (70.3%). Overall, respondents were hesitant in starting a related business due to the lack of government support and the complexity of the regulation process. Moreover, concerns about global market entry were similar. Being unfamiliar with the novel process and worrying about the achievement despite existing challenges were the biggest drawback. Conclusion: For the digital therapeutics industry to evolve domestically and internationally, government support and guidance are essential. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 연세대학교의과대학 | - |
dc.relation.isPartOf | Yonsei Medical Journal | - |
dc.title | Survey for Government Policies Regarding Strategies for the Commercialization and Globalization of Digital Therapeutics | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000746146100001 | - |
dc.identifier.doi | 10.3349/ymj.2022.63.S56 | - |
dc.identifier.bibliographicCitation | Yonsei Medical Journal, v.63, pp.56 - 62 | - |
dc.identifier.kciid | ART002804645 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85123462053 | - |
dc.citation.endPage | 62 | - |
dc.citation.startPage | 56 | - |
dc.citation.title | Yonsei Medical Journal | - |
dc.citation.volume | 63 | - |
dc.contributor.affiliatedAuthor | 문종윤 | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Digital therapeutics | - |
dc.subject.keywordAuthor | health policy | - |
dc.subject.keywordAuthor | government support | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.